Mirae Asset Global Investments
IRWD icon

Mirae Asset Global Investments’s Ironwood Pharmaceuticals IRWD Stock Holding History

Mirae Asset Global Investments’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$150K Sell
35,547
-1,143
-3% -$4.41K ﹤0.01% 1168
2026
Q1 		$129K Buy
36,690
+600
+2% +$2.46K ﹤0.01% 1142
2025
Q4 		$122K Buy
36,090
+29,810
+475% +$77.4K ﹤0.01% 1227
2025
Q3 		$8.23K Buy
6,280
+29
+0.5% +$30 ﹤0.01% 1595
2025
Q2 		$4.48K Buy
6,251
+752
+14% +$590 ﹤0.01% 1546
2025
Q1 		$7.75K Buy
5,499
+166
+3% +$395 ﹤0.01% 1493
2024
Q4 		$23.7K Sell
5,333
-444
-8% -$1.8K ﹤0.01% 1394
2024
Q3 		$23.2K Buy
5,777
+1,031
+22% +$5.54K ﹤0.01% 1412
2024
Q2 		$29.4K Sell
4,746
-89,937
-95% -$636K ﹤0.01% 1330
2024
Q1 		$936K Buy
94,683
+4,522
+5% +$54.9K ﹤0.01% 1577
2023
Q4 		$1.03M Sell
90,161
-899
-1% -$8.89K ﹤0.01% 1604
2023
Q3 		$877K Buy
91,060
+3,460
+4% +$33.9K ﹤0.01% 1584
2023
Q2 		$932K Buy
87,600
+901
+1% +$9.68K ﹤0.01% 1612
2023
Q1 		$912K Buy
86,699
+23,531
+37% +$264K ﹤0.01% 1596
2022
Q4 		$783K Buy
63,168
+58
+0.1% +$658 ﹤0.01% 1637
2022
Q3 		$654K Buy
63,110
+17,410
+38% +$197K ﹤0.01% 1720
2022
Q2 		$527K Buy
+45,700
New +$538K ﹤0.01% 1722
2017
Q1 		– Sell
-89,380
Closed -$1.15M – 656
2016
Q4 		$1.15M Buy
89,380
+23,548
+36% +$297K 0.03% 318
2016
Q3 		$876K Sell
65,832
-147
-0.2% -$1.72K 0.02% 366
2016
Q2 		$723K Sell
65,979
-83,849
-56% -$819K 0.02% 355
2016
Q1 		$1.37M Buy
149,828
+2,814
+2% +$23.2K 0.04% 270
2015
Q4 		$1.43M Buy
147,014
+1,533
+1% +$14.8K 0.05% 279
2015
Q3 		$1.27M Buy
145,481
+4,365
+3% +$40.7K 0.05% 266
2015
Q2 		$1.43M Buy
141,116
+21,597
+18% +$251K 0.05% 263
2015
Q1 		$1.6M Buy
119,519
+22,712
+23% +$298K 0.05% 235
2014
Q4 		$1.24M Sell
96,807
-2,185
-2% -$25K 0.05% 236
2014
Q3 		$1.07M Buy
+98,992
New +$1.13M 0.04% 264

Other funds holding IRWD

WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
CAMG
CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
SP
SmartHarvest Portfolios Poulsbo, Washington $309M AUM
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.94% 1-Year Est. Return

Mirae Asset Global Investments's IRWD Position: Q2 2026 in Review

Mirae Asset Global Investments reduced its Ironwood Pharmaceuticals (IRWD) stake by 3.1% in Q2 2026, selling an estimated $4.41K and leaving 35,547 shares worth $150K. The position accounts for ﹤0.01% of the portfolio, ranked #1168.

Mirae Asset Global Investments first reported a position in IRWD in Q3 2014 and has held it in 27 quarters since. The position peaked at $1.6M in Q1 2015. 45 funds tracked by Wall St. Rank hold IRWD as of Q2 2026.

  • Mirae Asset Global Investments held 35,547 shares of Ironwood Pharmaceuticals worth $150K as of Q2 2026.
  • Mirae Asset Global Investments sold 1,143 Ironwood Pharmaceuticals shares in Q2 2026, an estimated $4.41K.
  • Ironwood Pharmaceuticals made up ﹤0.01% of Mirae Asset Global Investments's portfolio in Q2 2026, its #1168 holding.
  • Mirae Asset Global Investments first reported a position in Ironwood Pharmaceuticals in Q3 2014 and has held it in 27 quarters since.
  • Mirae Asset Global Investments's Ironwood Pharmaceuticals position peaked at $1.6M in Q1 2015.
  • 45 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q2 2026.

Based on Mirae Asset Global Investments's 13F filing for Q2 2026, filed 22 Jul 2026.